CBD will go on sale in Australia, but first manufacturers will have to prove it works | Australia news

“YYou can drink as much whiskey as you like, but no whiskey is available, “said a psychopharmacologist and academic director of the Lambert Initiative for the treatment of cannabinoids when asked to explain the rules for CBD in Australia. Professor Iain McGregor says.

CBD is a compound found in cannabis plants, but unlike THC, it has no psychotropic effects. On February 1, it is legal for the Therapeutic Goods Department to down-schedule the substance from Schedule 4 (prescription drug) to Schedule 3 (pharmacist-only drug) and then purchase over-the-counter products containing low-dose cannabidiol (CBD). became. .. On December 15, the TGA announced its decision after a safety review showing that “the known adverse events of CBD at low doses were not serious.”

But anyone suffering from pain, anxiety, or simple curiosity trying to buy CBD would have received a disappointing response from a pharmacist this week. The substance itself is virtually legal, but products containing it are not approved by the Australian Therapeutic Products Registry (ARTG). This is a sales requirement.

The efficacy of CBD in Australia is very different from that of other countries available without a prescription, such as the United Kingdom and the United States. In the UK, low doses of CBD oil can be sold as a dietary supplement, but not as a medicine. In the United States, the substance is not approved at the federal level, but in some states you can buy everything from pet food to bottled water to Martha Stewart-branded gummies, including CBD. “You have this runaway train that goes far beyond the evidence available,” says McGregor.

“Currently approved, companies need to show that their products are both safe and effective in order to bring them to market.

“And there’s the problem-there’s no good clinical trial showing 150 mg of CBD [the daily dose approved by the TGA] It’s really effective. “

“I don’t know if it works,” said Yvonne Bonomo, an addiction medicine physician and senior researcher at the Australian Center for Cannabinoid Clinical Research Excellence. “It may work for some people. It’s hard to know. So we need to see it.”

“If it’s going to be treated as a drug, it has to go through the process of passing the drug,” she says. “Other countries are using different routes to make it available, and they have different ways that are less rigorous.”

Bonomo emphasizes the importance of quality control and states that prior work is valuable in the long run. “The products listed on ARTG have a process. This is a complex process, but it is necessary to ensure that these high quality products are on the list.”

The Australian Medical Association does not support TGA’s decision to down-schedule substances due to the lack of products listed on the ARTG, along with the potential for interaction with prescription drugs and the need for more evidence. It was.

“We are filling the 70-year Prohibition gap that has not been studied,” said Tommy Huppert, CEO of Australian cannabis grower and manufacturer Cannatrek. Huppert’s company has just signed an exclusive supply agreement with Chemist Warehouse, but it’s still unclear what exactly it will supply. “Everyone is really competing to bring a product to market. What mountain do you have to climb? Will it be weeks? Months?” He wonders.

ARTG registration is a high hurdle, but the table has enormous potential revenue. Tim Drally, director of Southern Cannabis Holdings, believes that the over-the-counter market for CBD oil “exceeds $ 200 million annually.”

The fact that CBD is found in plants subject to three separate UN treaties is not the only thing that sets it apart from other drugs. It’s also different because “we’re talking about really common active substances,” says Huppert. CBD manufacturers need to conduct clinical trials to find out for what purpose existing widely used substances actually work, rather than developing new drugs for a specific purpose. Or, as McGregor says, “the exact opposite of most drug development.”

There are many wild health claims about the properties of CBD oil (TGA fines have been imposed in the past). There is also plenty of anecdotal evidence that CBD can help with everything from insomnia to chronic pain, anxiety and epilepsy. Clinical trial data support some of these claims, but only at doses much higher than TGA approved.

“The challenge now is the process of proving. [the anecdotal evidence] … To list drugs with an objective claim, ”says Huppert. “It usually takes years and millions of dollars to bring a drug to market.”

And when it arrives, it can be a price that keeps out many people. In the UK, a bottle containing 300 mg of CBD oil (enough to use for 2 days at the TGA approved level) costs about A $ 40.

“You’re not talking about the prices of vitamins and turmeric … you’re talking about the products that are highly sought after,” says McGregor. “That’s the story we hear over and over again. [from patients], They can’t afford the product. “

Currently, ARTG lists only one prescription CBD product for use in Australia. This is Epidyolex approved for the treatment of severe pediatric epilepsy. This is a much narrower range than the perceived potential of matter.

Under the Lambert Initiative, McGregor is conducting multiple clinical trials using low doses of CBD oil. He will soon launch it for his self-aware cohort, “the moody middle-aged people who can’t sleep well.” He said it was a “placebo-controlled clinical trial … and by the end of the trial, the dose range was that mildly moody and not sleeping-well, pretty good about whether you’re doing something gently. You will have an idea, “says unpleasant demographics. “

But even if that study, or a study by the manufacturer, proves that low-dose CBD is effective, he says it will take “6-12 months” for CBD products to become available in pharmacies. believe.

Bonomo believes that certainty is worth the wait. “We’re learning more about how it works and the groups it seems to benefit. I think we’re on the right track. We’re moving forward cautiously and safely. But move forward. “